Surging Prevalence Of Rare Diseases Powers Growth Of The Orphan Drugs Market: Major Factor in the Transformation of the Orphan Drugs Market in 2025

How Will the Orphan Drugs Market Grow, and What Is the Projected Market Size?
In the past few years, there has been a notable expansion in the size of the market for orphan drugs. An upsurge from $188.45 billion in 2024 to $208.04 billion in 2025 is expected, reflecting a compound annual growth rate (CAGR) of 10.4%. This growth within the historical timeframe can be linked to the Orphan Drug Act of 1983, a heightened focus on rare diseases, drug repositioning, developments in genetic comprehension, and research funding initiatives.

The market size of orphan drugs is anticipated to witness substantial expansion in the upcoming years. It is set to reach $481.69 billion by 2029 with a compound annual growth rate (CAGR) of 23.4%. The progression during the predicted timeframe is linked to emerging market access policy changes, healthcare initiatives based on value, worldwide market widening, patient-focused drug innovation, and focus on unusual cancers. Key trends accompanying the growth in the prediction period involve heightened target identification, expedited regulatory procedures, advancements in gene therapy, broadened research partnerships, and precision medicine strategies.

What Key Elements Are Boosting Growth in the Orphan Drugs Market?
The growth of the orphan drugs market is significantly influenced by the increasing occurrence of rare diseases. These diseases, which affect only a small fraction of the population, often necessitate a cold chain - a temperature-regulated supply chain that is not universally available. Orphan or rare diseases are infrequently observed in the population, affecting just 7 out of 10,000 individuals. Despite their rarity, the global rate of these diseases is on the rise. For example, an article published by the American Cancer Society in January 2022 stated that each year, approximately 54,000 fresh cases of oropharyngeal or oral cancer are diagnosed in the USA, with 11,230 fatalities. Typically, most of these diagnoses occur at the average age of 63, but these cancers can affect younger individuals too. Around 20% (1 in 5) of these cases involve patients below the age of 55. Therefore, the escalating prevalence of rare diseases propels the expansion of the orphan drugs market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2823&type=smp

Who Are the Major Industry Players Fueling Orphan Drugs Market Expansion?
Major companies operating in the orphan drugs market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Farbenfabriken Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Novo Nordisk A/S, Merck & Co. KG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., CSL Limited, Biogen Inc., Celgene Corporation, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Grifols SA, Alexion Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Aegerion Pharmaceuticals Inc., Sankyo Co. Ltd.

Which Key Developments Are Influencing the Orphan Drugs Market?
The endorsement of biological orphan drugs for various indications serves as a crucial trend propelling the expansion of the orphan drugs market. These biological medicines, utilized for rare diseases including cancer, have fewer side effects, and are prevalent in the developed world. For example, Cardax, Inc. declared its engagement with Frederick D. Sancilio, Ph.D., a biological orphan drug specialist, to initiate its biological orphan drug development program. To develop commercial products, businesses are concentrating on procuring biological orphan drugs to boost their revenues.

How Is the Segmentation of the Orphan Drugs Market Defined?
The orphan drugs market covered in this report is segmented -

1) By Therapy Area: Oncology, Blood, Central Nervous System, Endocrine, Cardiovascular, Respiratory, Immunomodulatory
2) By Diseases Type: Oncology, Hematology, Neurology, Cardiovascular, Other Disease Types
3) By Drug Type: Biological, Non-Biological
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Sales

Subsegments:
1) By Oncology: Targeted Therapies, Chemotherapy Agents, Immunotherapy Drugs, Hormonal Therapies
2) By Blood: Hematopoietic Growth Factors, Coagulation Factor Concentrates, Treatments for Rare Blood Disorders
3) By Central Nervous System: Medications for Rare Neurological Disorders, Antiepileptic Drugs for Rare Epilepsy Syndromes, Treatments for Rare Neurodegenerative Diseases
4) By Endocrine: Hormonal Replacement Therapies, Treatments for Rare Endocrine Disorders
5) By Cardiovascular: Medications for Rare Cardiovascular Conditions, Treatments for Rare Genetic Heart Disorders
6) By Respiratory: Therapies for Rare Respiratory Diseases, Medications for Rare Allergic Conditions
7) By Immunomodulatory: Treatments for Rare Autoimmune Disorders, Immunotherapies for Rare Inflammatory Conditions

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/orphan-drug-global-market-report

What Is the Leading Region in the Orphan Drugs Market?
The countries covered in the orphan drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Is Covered In The Orphan Drugs Global Market Report?

- Market Size Analysis: Analyze the Orphan Drugs Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Orphan Drugs Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Orphan Drugs Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Orphan Drugs Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2823

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.